Waters (WAT) Expected to Announce Earnings on Monday

Waters (NYSE:WAT) is projected to release its Q2 2025 earnings data before the market opens on Monday, August 4th. Analysts expect Waters to post earnings of $2.92 per share and revenue of $745.96 million for the quarter. Waters has set its Q2 2025 guidance at 2.880-2.980 EPS and its FY 2025 guidance at 12.750-13.050 EPS.

Waters (NYSE:WAT) last announced its quarterly earnings results on Tuesday, May 6th. The medical instruments supplier reported $2.25 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.03. The company had revenue of $661.71 million during the quarter, compared to analysts’ expectations of $655.50 million. Waters had a return on equity of 41.70% and a net margin of 22.02%. Waters’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the business earned $2.21 earnings per share. On average, analysts expect Waters to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Waters Stock Up 1.4%

Shares of WAT stock opened at $302.62 on Monday. The stock has a 50 day moving average of $338.12 and a 200 day moving average of $357.95. The company has a current ratio of 1.81, a quick ratio of 1.28 and a debt-to-equity ratio of 0.69. The stock has a market cap of $18.01 billion, a P/E ratio of 27.46, a P/E/G ratio of 2.99 and a beta of 1.10. Waters has a twelve month low of $279.61 and a twelve month high of $423.56.

Institutional Trading of Waters

Several large investors have recently made changes to their positions in the company. Empowered Funds LLC increased its position in shares of Waters by 16.6% during the first quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier’s stock worth $415,000 after purchasing an additional 160 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Waters by 3.6% during the first quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier’s stock worth $73,733,000 after purchasing an additional 6,976 shares in the last quarter. Integrated Wealth Concepts LLC increased its position in shares of Waters by 2.9% during the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after purchasing an additional 30 shares in the last quarter. Finally, Brighton Jones LLC increased its position in shares of Waters by 112.9% during the fourth quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier’s stock worth $471,000 after purchasing an additional 673 shares in the last quarter. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

WAT has been the subject of several recent research reports. Wall Street Zen cut Waters from a “buy” rating to a “hold” rating in a research report on Saturday. Scotiabank reiterated a “sector outperform” rating and set a $465.00 price target on shares of Waters in a research report on Friday, July 11th. Jefferies Financial Group reiterated a “buy” rating on shares of Waters in a research report on Monday, July 14th. Bank of America lifted their price target on Waters from $370.00 to $375.00 and gave the company a “neutral” rating in a research report on Thursday, June 26th. Finally, KeyCorp upgraded Waters from a “sector weight” rating to an “overweight” rating and set a $460.00 price target for the company in a research report on Monday, March 31st. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $381.94.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.